Expanding Biomarker Testing in Early-stage Non-small Cell Lung Cancer
Comprehensive biomarker testing in early-stage NSCLC requires coordination across multiple specialties, including thoracic surgery, medical oncology, pathology, pulmonology, and radiology.
Comprehensive biomarker testing at the time of early NSCLC diagnosis is critical because it ensures that clinicians identify actionable molecular alterations before definitive treatment plans are set.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Teclistamab Plus Daratumumab Significantly Improves Survival in R/R Myeloma
2
Pirtobrutinib Superior to BR in First-Line CLL/SLL: BRUIN CLL-313 Results
3
Poll Results Reveal Readers’ Top Abstracts at SABCS 2025
4
Pelabresib Plus Ruxolitinib Benefits Spleen, Symptoms in Myelofibrosis
5
